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Summary 
 
The effects of chronic treatment with oxprenolol (CAS 6452-72-7) (OXP, 15 mg/ 
kg/day), or glibenclamide (CAS 10238-21-8) (GL, 2.5 mg/kg/day), or their 
combination administered for 6 and 12 weeks, on the butyrylcholinesterase (BuChE) 
activity in plasma and liver and on the plasma levels of triglycerides, total cholesterol 
and high density lipoprotein (HDL)-cholesterol were studied in normal, non-diabetic 
female rats. In all treated groups a significant increase of plasma BuChE activity was 
obtained after 6 weeks of either OXP (46%), or GL (36%) treatment, or of their 
concurrent application (24%). After 12 weeks of treatment, the increase in enzyme 
activity was significant only in the OXP group. The BuChE activity in the liver was 
increased (between 3-25%) in all treated groups except in one during 6 and 12 weeks 
of treatment. These effects of either OXP or GL, or their combination on BuChE 
activity in liver suggest their stimulating effects on enzyme synthesis. The changes of 
total plasma cholesterol in all groups were insignificant. On the other hand, HDL-
cholesterol was significantly decreased in all treated groups. After 6 weeks of 
treatment, GL, OXP, or their combination caused a decrease in plasma HDL 
cholesterol by 19, 50 or 22% respectively, when compared with the control group. 
After 12 weeks of GL, OXP, or GL+OXP administration, HDL-cholesterol plasma 
levels in treated groups were 32, 25 and 22% lower than in the control group. 
Treatment with GL, OXP, or GL+OXP during 6 weeks had no significant effect on 
triglycerides level. However, after 12 weeks of GL, OXP, or GL+OXP 
administration, the triglycerides levels were significantly increased (9, 47 and 36%) 
when compared with the control group. These results have shown, that the increase in 
BuChE activity might be the first sign of altered triglyceride and lipoprotein 
metabolism. 
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1. Introduction 
Butyrylcholinesterase (EC3.1.1.8, acylcholine acylhydrolase, serum 
cholinesterase, butyrylcholinesterase, BuChE) is still an enzyme with unknown 
physiological function, although its structure, cloning and chromosome localization 
for enzyme in humans is known [1-3]. Beside the liver, where BuChE is synthesised 
and released into serum immediately following its synthesis, the enzyme is found to a 
lesser extent in the adipose tissue, small intestine, smooth muscle and other tissues 
[1,4]. In a mammalian organism, BuChE has no known biological substrate, but it 
hydrolyses a variety of choline esters including butyrylthiocholine [1]. The clinical 
importance of BuChE lies in its pharmacological property of hydrolysing the short-
acting relaxant suxamethonium and ester type local anaesthetics (e.g. procaine and 
tetracaine hydrochloride) [5-7]. Therefore, a significant reduction in BuChE activity 
(e.g., due to liver disease, cancer, uraemia, treatment with glucocorticoids, reversible 
or irreversible cholinesterase inhibitors, etc.) may increase the intensity and duration 
of action of succinylcholine and the systemic toxicity of ester-type local anaesthetics 
[8-10]. In contrary, the increase of BuChE activity in anaesthesiology is of minor 
clinical significance. 
The fact, that the BuChE activity is increased in certain metabolic disorders is 
known for a long time [11]. High BuChE activities are typical for patients with 
hypercholesterolemia, hypertension, obesity and Type I or Type II diabetes [12-17]. 
In such patients, BuChE activity correlates strongly and positively with serum levels 
of low density lipoprotein (LDL)-cholesterol and triglycerides (TG) and inversely 
with serum high density lipoprotein (HDL)-cholesterol. Similar changes were 
observed in animals [13]. Fat Zucker rats that exhibited a marked increase in VLDL-
cholesterol have high serum BuChE activity [18]. Osada et al. have found that BuChE 
could be involved in the regulation of serum phospholipids level [19]. All these 
observations suggest a relationship between BuChE activity and lipoprotein 
metabolism, but the rationale for this connection is unclear. 
Some antihypertensive agents also show similar changes of serum lipids. For 
example, a significant increase of serum TG levels and a decrease of HDL-cholesterol 
occurs in patients on chronic propranolol or oxprenolol treatment [20,21]. Unlike 
some investigators who claimed that beta-blocking drugs cause a reduction of BuChE 
activity in vitro and in vivo in rats [22,23], a significant increase of total cholesterol 
(TC) and BuChE after chronic oxprenolol (OXP) treatment during 6, 10 and 12 weeks 
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was shown in our experiments [24]. The increase of TG levels after 12 weeks of OXP 
treatment was not significant. We suppose that the increase of enzyme activity was 
initially due to the action of OXP on TC and TG metabolism, and not due to its direct 
effect on the enzyme.  
Like OXP, prolonged administration of glibenclamide (GL) to normal rats 
causes an increase of serum lipids [25]. Therefore, it was interesting to assess whether 
these changes are also simultaneously accompanied by the changes in BuChE activity. 
Since concurrent treatment with GL and OXP in the same patients is sometimes used, 
we investigated the effects of GL in combination with OXP on BuChE activity and 
serum lipids as well as BuChE activity in the liver. 
 
2. Materials and Methods 
2.1. Test substances 
The non-selective β-blocker oxprenolol (CAS 6452-72-7) and the antidiabetic 
drug glibenclamide (CAS 10238-21-8) obtained from Research Institute Pliva, 
Zagreb, Croatia, were used in our experiments. 
2.2. Test animals 
Female Wistar rats (Department of Pharmacology, School of Medicine, 
University of Zagreb, Zagreb, Croatia) weighting 130-150 g were used in the studies. 
The animals were maintained under controlled laboratory conditions. Standard diet 
(food for laboratory rats and mice was manufactured by PLIVA, Kalinovica, Croatia) 
in pellet form was available ad libitum in control groups. OXP and GL were mixed in 
standard diet and offered to animals ad libitum in pellet form. Calculations for the 
concentration of OXP and GL in diet were performed according to the group mean 
body weight and group mean food consumption. The doses were expressed as mg of 
OXP/kg and as mg of GL/kg of body weight/day. Handling and treatment of the 
animals were conducted on basis of the international guidelines regarding use of 
laboratory animals. The experiments have been approved by local ethics committee. 
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2.3. Study design and dosage 
The seventy animals were divided in two control groups (n=7 each) and six 
experimental groups. Two experimental groups (n=8 each) were on treated diet with 
OXP (15 mg/kg/day) for 6 and 12 weeks. The remainder four groups (each=10) were 
on treated diet with GL (2.5 mg/kg/day) or with a combination of OXP and GL in the 
same doses for 6 and 12 weeks. The animals were anaesthetised with ether. Blood 
samples were obtained by cardiac punction. Before collecting liver tissue, the liver 
had been washed out of blood in situ, with saline via the vena cava superior. Serum 
and liver samples were stored at 20° C until analysed. For the analysis, liver tissues 
were homogenised with normal saline in the ratio of 1: 5. The supernatants were 
obtained by centrifuging the homogenised samples at 16000 g for 15 min, at 4° C. 
Glucose in whole blood was determined by a glucohaemo test 1-45, Pliva.  
BuChE activity was measured using the spectrophotometric method of Ellman et al. 
with butyrylthiocholine (Sigma, ChemCo, St. Louis, USA) as a substrate [26]. BuChE 
measurements were carried out in the presence and absence of 10-4 M ethopropazine 
hydrochloride (Sigma, ChemCo, St. Louis, USA), a specific BuChE inhibitor, in order 
to exclude the effect of acetycholinesterase. Enzyme activities are expressed as µmol 
of substrate hydrolysed per min per ml of serum or g of tissue wet weight. 
Concentrations of total cholesterol and triglycerides in the serum were determined by 
cholesterol enzymatic colorimetric test (Pliva, Pharmaceutical, Chemical, Food and 
Cosmetic Industry, Zagreb, Croatia). HDL cholesterol was estimated after 
precipitation of VLDL and LDL cholesterol with PEG 20 000 (Quantolip HDL 
Immuno AG Vienna) and measured in supernatant by the cholesterol enzymatic 
colorimetric test (PLIVA, Pharmaceutical, Chemical, Food and Cosmetic Industry, 
Zagreb, Croatia). The concentrations were expressed as mmol/L. 
 
2.4. Statistical analysis 
Data are shown as mean ± standard error of the mean. 
Analysis of variance (ANOVA) was performed to compare the results from 
weeks 6 and 12. Normality of the data was tested with Kolmogorov test. The 
assumption of equal group variances was tested with Levene’s test. 
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The post-hoc test was Newman-Keuls test for group comparison. The results were 
considered as significant with p≤ 0.05. 
 
3. Results  
3.1. Clinical observation 
The administration of GL or OXP, or their concurrent use did not induce any changes 
in the animal behaviour. There was no influence of both agents on body weight or 
food consumption when compared with the control groups. 
 
3.2. Effect on serum glucose levels 
After 12 weeks of treatment, GL, or OXP, or their combination induced an 
insignificant increase of serum glucose levels by 33.7%, 17.3% and 25.6% 
respectively, when compared with the control group and the treated animals after 6 
weeks of treatment.  
 
3.3. Effects on BuChE activity 
Serum 
Six weeks of treatment: The administration of GL or OXP induced a significant 
increase in BuChE activity (36 and 46%) in comparison with control. The increase of 
BuChE activity after their concurrent application was lower, but also significant 
(24%, vs. control). 
Twelve weeks of treatment: Serum BuChE activity was significantly elevated only 
after the OXP treatment (19%, p< 0.05 vs. control) while the increase of enzyme 
activity after GL or GL+OXP combination was small and insignificant. 
 
Liver 
Six and twelve weeks of treatment: GL or OXP or their concurrent administration 
induced an insignificant increase of BuChE activity (3-25%) in all groups except in 
the group on OXP treatment for 12 weeks. In this group, OXP treatment caused an 
insignificant decrease of BuChE activity by 5%. 
 
3.4. Effects on serum lipids  
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Insignificant changes, i.e. a decrease of total cholesterol for 8-14%, were noted only 
after 12 weeks of treatment with GL or OXP or their concomitant administration. On 
the other hand, HDL-cholesterol significantly decreased in all treated groups. After 6 
weeks of treatment, GL, OXP or their combination caused a decrease of HDL 
cholesterol (19, 50 or 22% respectively), when compared with the control. After 12 
weeks of GL, OXP, or GL+OXP administration, the concentrations of HDL-
cholesterol in treated groups were 31, 25 and 22% lower than in the control group. 
Treatment with GL, OXP, or GL+OXP during 6 weeks had no significant effect on 
triglycerides levels. However, after 12 weeks of GL, OXP, or GL+OXP 
administration, the triglycerides levels were significantly higher (9, 47 and 36%) 
when compared with the control group. 
The decrease of HDL-cholesterol was not time dependent, but the increase of 
triglycerides was. 
 
4. Discussion 
We have shown a significant increase of serum BuChE activity (46%) after 6 
weeks of OXP treatment. The increase after 12 weeks of treatment was insignificant 
(Table 1). These results are congruent with our earlier results obtained in male rats, 
which have also shown a significant increase in BuChE activity (27-51%) after 6, 10 
and 12 weeks of OXP treatment [24]. Therefore, we have suggested that the sex-
related differences concerning OXP effect on BuChE activity do not exist. The results 
of serum BuChE activity after GL treatment resemble those with OXP, i.e. the 
enzyme activity was significantly increased (36%) after 6 weeks of treatment  and the 
same as in control after 12 weeks of treatment (Table 1). The BuChE activity in the 
liver increased or was the same as in control after 6 and 12 weeks of OXP or GL 
treatment or their combination (Table 1). Although the increase of BuChE activity in 
the liver after OXP or GL treatment was insignificant during both time intervals, these 
results prove a stimulating effect of OXP and GL on enzyme synthesis.  
The stimulating effects of OXP on BuChE activity in serum and liver support 
the data showing that at least one beta-blocker does not inhibit the BuChE activity. 
This is different from the results of some other authors, who have found that 
propranolol, timolol and sotalol inhibit the BuChE activity in human serum as well as 
in heart and brain tissue in vitro and in vivo [22,23,27]. Alike, Hellenbrecht and 
Mueller have found that β-sympatholytics are non-specific inhibitors of serum BuChE 
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in vitro, and that the degree of BuChE inhibition directly depends on the hydrophobic 
properties of these drugs [28]. We have suggested that, due to the small partition 
coefficient and slight liposolubility, OXP has little affinity for BuChE, and that this is 
the main reason why this beta-blocker when compared with other drugs from the 
same group did not cause BuChE inhibition. We are also sure, that the increase of 
enzyme activity in liver and plasma is the consequence of direct interference of OXP 
with metabolism of TG, HDL, and/or TC, and that this is not due to OXP direct effect 
on the enzyme. Ryhanen et al have shown, that when cholesterol content in LDL 
particles is increased , the BuChE activity also increased. In HDL particles the 
situation is opposite, i.e. when cholesterol content in HDL increases, the enzyme 
activity is diminished [29]. According to our results (Table 1), a significant increase 
of TG by 47% (p<0.05) was found after 12 weeks of OXP treatment, and an 
significant decrease of HDL by 50% and 25% (p<0.05), occurred after 6 and 12 
weeks of  OXP treatment. During all this period, the BuChE activity was increased, or 
the same as in control. 
 
These adverse effects of OXP on serum lipids in humans and animals are well 
known, but they are not consistent. In patients, a significant increase in serum TG, no 
change in TC and a decrease in HDL-cholesterol during OXP treatment was observed 
by Day et al [30]. However, no significant changes in TC, TG and HDL-cholesterol 
have been reported by Ferrara et al [31]. The full explanation of the mechanisms of 
the lipid modifying effects of these antihypertensive drugs remains unresolved, since 
different factors can be responsible. For example, a beta-blocker may decrease HDL 
and increase TG by decreasing lipoprotein lipase activity or lecithin:cholesterol 
acyltransferase (LCAT) activity [32].  
The positive correlation of BuChE activity and serum TG we have proved, 
agrees with the results of other investigators, who have shown that the induction of 
diabetes in rats caused an increase in both BuChE activity and serum TG 
concentrations, while treatment with insulin resulted in normalization of these values 
[13]. Administration of a specific inhibitor of BuChE after induction of diabetes in 
these animals also reversed hypertriglyceridemia [13]. In a study on patients with 
diabetes type I or type II, BuChE activity correlated positively with TG concentration 
and inversely with insulin sensitivity [14].  
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Our results show that chronic treatment with GL caused a significant decrease 
of HDL-cholesterol by 19% and 32% after 6 and 12 weeks of treatments (Table 1). 
The 9% increase of TG (p<0.05) observed after 12 weeks of GL treatment, was very 
low in comparison with TG values after treatment with OXP or OXP+GL 
combination in the same period (Table 1). Since the increase of TG after OXP 
treatment was 1.3 times greater than the one after GL treatment, we suggest that the 
significant increase of TG by 36% after concurrent administration OXP and GL is the 
consequence of OXP action and not of GL. Concurrent use of GL and OXP had no 
additional effect on serum and liver BuChE activity, neither HDL-cholesterol. Also, 
the changes in BuChE activity and HDL-cholesterol were not time dependent. 
However, the TG concentration was significantly higher only after 12 weeks of OXP 
or OXP+GL treatment. 
The data about the influence of GL and other sulphonylureas on lipid 
metabolism in non-diabetic or diabetic animals and diabetic patients are also 
inconsistent. According to George and Augusti, prolonged administration of GL (50 
µg/kg daily, during 2 months) in normal rats, significantly decreased blood sugar, 
liver glycogen and protein, and significantly increased liver and serum lipids (e.g. 
triglyceride glycerol, total and free cholesterol) [33]. The triglyceride was more 
increased in the serum (35%) than in the liver (23%). GL administered at maximal 
clinical doses (0.4 mg/kg, daily intraperitoneal injection) to adult male Sprague-
Dawley rats for 8 weeks, did not alter serum cholesterol, HDL-cholesterol or the 
TC:HDL-cholesterol ratio [34]. Gaafar et al have found that GL in daily dose of 2.5 
mg/kg during 15, 30 and 60 days showed the hypercholesterolemic effect in non-
diabetic rats [35]. Contrary to normal rats, GL has a significant hypocholesterolemic 
effect in aloxan diabetic rats [35]. While some studies on type 2 diabetes patients have 
shown an improvement in serum triglycerides during sulphonylurea therapy, other 
have failed. Most of the studies have failed to show a consistent effect on HDL 
cholesterol concentrations despite substantial improvements in glycaemia [25]. All 
these data in humans and animals suggest that the mode of action of sulphonylureas is 
still poorly understood.  
Our findings on the relationship between the increase of BuChE activity and 
decreased level of HDL and/or increased TG level in experimental animals after 
treatment with OXP, or GL or both together, correspond well with the results of other 
authors who suggest that BuChE is connected with changes in lipid metabolism. The 
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data of Rustemeijer et al., who have found that BuChE activity in type II diabetes is 
directly related to TG synthesis, support this hypothesis [17]. The same authors also 
consider that the measurement of BuChE activity may therefore be a useful tool in the 
choice of drug for treatment of hypertriglyceridaemia in patients with diabetes.  
Conclusion. Our results in non-diabetic rats show that chronic oxprenolol or 
glibenclamide treatment or their concurrent use during 6 and 12 weeks induce the 
increase of serum and liver BuChE activity. This, however, is not due to their direct 
effect on the enzyme, but to the consequence of altered lipid metabolism caused by 
oxprenolol and glibenclamide. Since BuChE activity was increased earlier than serum 
TG concentration, we suggest that the increase in BuChE activity might be the first 
sign of altered triglyceride metabolism. Our results have also shown that the 
synergistic action of GL and OXP combination on BuChE activity and plasma lipids 
does not exist. 
Concerning these results about the relationship between BuChE and lipid 
metabolism lipids, further studies are clearly needed. 
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LDL-cholesterol low density lipoprotein 
OXP   oxprenolol 
TGs   triglycerides 
TC   total cholesterol 
 
 
 16 
 
 
Table 1. BuChE activities in plasma and liver, and serum lipids (Mean±SD) in female non-diabetic rats 
after the chronic oral administration of oxprenolol (15 mg/kg/day), or glibenclamide (2.5 mg/kg/day) or 
their concomitant administration. Relative changes are in brackets. 
 
 
* Indicates a statistically significant difference (p<0.05) when compared with the control group. 
OXP – oxprenolol 
GL - glibenclamide  
  
 
 
Time – 
weeks 
Treatment Glucose 
mmol/L 
BuChE-plasma 
µmol/min/mL 
(%) 
BuChE-liver 
µmol/min/g 
tissue  (%) 
Total 
Cholesterol 
concn. mmol/l 
(%) 
HDL- 
Cholesterol 
concn. mmol/l 
(%) 
Triglycerides 
Concn 
mmol/l 
(%) 
 
 
 
 
6 
 
Control 
 
OXP 
 
GL 
 
OXP+GL 
 
9.42±0.95 
(100) 
9.0±0.6 
(96) 
9.5±0.9 
(102) 
8.4±0.3 
(89) 
 
 
0.41±0.04 
(100) 
0.60±0.03* 
(146) 
0.56±0.05* 
(136) 
0.51±0.04* 
(124) 
 
0.87±0.96 
(100) 
1.1±0.1 
(125) 
0.90±0.1 
(103) 
1.02±0.1 
(117) 
 
1.64±0.09 
(100) 
1.7±0.1 
(101) 
1.7±0.1 
(109) 
1.6±0.1 
(97) 
 
0.32±0.03 
(100) 
0.16±0.02* 
(50) 
0.26±0.04* 
(81) 
0.25±0.03* 
(78) 
 
 
1.15±0.07 
(100) 
1.1±0.1 
(92) 
1.2±0.2 
(91) 
1.2±0.2 
(93) 
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Control 
 
OXP 
 
GL 
 
OXP+GL 
 
6.87±0.51 
(100) 
9.1±0.9 
(134) 
8.1±0.4 
(117) 
8.6±0.4 
(126) 
 
 
0.59±0.03 
(100) 
0.70±0.05* 
(119) 
0.6±0.0 
(103) 
0.6±0.0 
(110) 
 
1.09±0.07 
(100) 
1.0±0.1 
(95) 
1.3±0.1 
(120) 
1.2±0.1 
(113) 
 
1.96±0.19 
(100) 
1.8±0.1 
(92) 
1.7±0.1 
(86) 
1.7±0.1 
(86) 
 
1.07±0.09 
(100) 
0.80±0.07* 
(75) 
0.74±0.07* 
(68) 
0.83±0.04* 
(78) 
 
1.2±0.15 
(100) 
1.87±0.35* 
(147) 
1.39±0.21* 
(109) 
1.73±0.09* 
(136) 
